471 related articles for article (PubMed ID: 19207292)
1. Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss.
Jacob S; Rabbia M; Meier MK; Hauptman J
Diabetes Obes Metab; 2009 Apr; 11(4):361-71. PubMed ID: 19207292
[TBL] [Abstract][Full Text] [Related]
2. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients.
Halpern A; Mancini MC; Suplicy H; Zanella MT; Repetto G; Gross J; Jadzinsky M; Barranco J; Aschner P; Ramirez L; Matos AG
Diabetes Obes Metab; 2003 May; 5(3):180-8. PubMed ID: 12681025
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
4. A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin.
Berne C;
Diabet Med; 2005 May; 22(5):612-8. PubMed ID: 15842517
[TBL] [Abstract][Full Text] [Related]
5. Orlistat in the treatment of overweight or obese Chinese patients with newly diagnosed Type 2 diabetes.
Shi YF; Pan CY; Hill J; Gao Y
Diabet Med; 2005 Dec; 22(12):1737-43. PubMed ID: 16401321
[TBL] [Abstract][Full Text] [Related]
6. Effect of orlistat on glycaemic control in overweight and obese patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.
Aldekhail NM; Logue J; McLoone P; Morrison DS
Obes Rev; 2015 Dec; 16(12):1071-80. PubMed ID: 26345590
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial.
Kelley DE; Bray GA; Pi-Sunyer FX; Klein S; Hill J; Miles J; Hollander P
Diabetes Care; 2002 Jun; 25(6):1033-41. PubMed ID: 12032111
[TBL] [Abstract][Full Text] [Related]
8. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial.
Hanefeld M; Sachse G
Diabetes Obes Metab; 2002 Nov; 4(6):415-23. PubMed ID: 12406041
[TBL] [Abstract][Full Text] [Related]
9. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study.
Hollander PA; Elbein SC; Hirsch IB; Kelley D; McGill J; Taylor T; Weiss SR; Crockett SE; Kaplan RA; Comstock J; Lucas CP; Lodewick PA; Canovatchel W; Chung J; Hauptman J
Diabetes Care; 1998 Aug; 21(8):1288-94. PubMed ID: 9702435
[TBL] [Abstract][Full Text] [Related]
10. Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients.
Derosa G; Maffioli P; Ferrari I; D'Angelo A; Fogari E; Palumbo I; Randazzo S; Cicero AF
Fundam Clin Pharmacol; 2011 Oct; 25(5):642-51. PubMed ID: 21077943
[TBL] [Abstract][Full Text] [Related]
11. Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes.
Kelley DE; Kuller LH; McKolanis TM; Harper P; Mancino J; Kalhan S
Diabetes Care; 2004 Jan; 27(1):33-40. PubMed ID: 14693963
[TBL] [Abstract][Full Text] [Related]
12. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin.
Miles JM; Leiter L; Hollander P; Wadden T; Anderson JW; Doyle M; Foreyt J; Aronne L; Klein S
Diabetes Care; 2002 Jul; 25(7):1123-8. PubMed ID: 12087008
[TBL] [Abstract][Full Text] [Related]
13. The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss.
Rowe R; Cowx M; Poole C; McEwan P; Morgan C; Walker M
Curr Med Res Opin; 2005 Nov; 21(11):1885-90. PubMed ID: 16307710
[TBL] [Abstract][Full Text] [Related]
14. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor.
Finer N; James WP; Kopelman PG; Lean ME; Williams G
Int J Obes Relat Metab Disord; 2000 Mar; 24(3):306-13. PubMed ID: 10757623
[TBL] [Abstract][Full Text] [Related]
15. Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes.
Derosa G; Cicero AF; D'Angelo A; Fogari E; Maffioli P
J Clin Pharm Ther; 2012 Apr; 37(2):187-95. PubMed ID: 21812797
[TBL] [Abstract][Full Text] [Related]
16. Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical).
Kopelman P; Groot Gde H; Rissanen A; Rossner S; Toubro S; Palmer R; Hallam R; Bryson A; Hickling RI
Obesity (Silver Spring); 2010 Jan; 18(1):108-15. PubMed ID: 19461584
[TBL] [Abstract][Full Text] [Related]
17. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
[TBL] [Abstract][Full Text] [Related]
18. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.
Muls E; Kolanowski J; Scheen A; Van Gaal L;
Int J Obes Relat Metab Disord; 2001 Nov; 25(11):1713-21. PubMed ID: 11753595
[TBL] [Abstract][Full Text] [Related]
19. The effect of orlistat-induced weight loss, without concomitant hypocaloric diet, on cardiovascular risk factors and insulin sensitivity in young obese Chinese subjects with or without type 2 diabetes.
Tong PC; Lee ZS; Sea MM; Chow CC; Ko GT; Chan WB; So WY; Ma RC; Ozaki R; Woo J; Cockram CS; Chan JC
Arch Intern Med; 2002 Nov; 162(21):2428-35. PubMed ID: 12437401
[TBL] [Abstract][Full Text] [Related]
20. The use of orlistat in the treatment of obesity, dyslipidaemia and Type 2 diabetes.
Nelson RH; Miles JM
Expert Opin Pharmacother; 2005 Nov; 6(14):2483-91. PubMed ID: 16259579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
